A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
- 24 February 2011
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 29 (10), 1948-1958
- https://doi.org/10.1016/j.vaccine.2010.12.104
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneVaccine, 2008
- Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccinationVirology, 2008
- Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humansNature Medicine, 2008
- Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East AfricaVaccine, 2008
- Toward an AIDS VaccineScience, 2008
- An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesThe Journal of Experimental Medicine, 2008
- Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus VectorsJournal of Virology, 2007
- IL-2 Regulates Expansion of CD4+ T Cell Populations by Affecting Cell Death: Insights from Modeling CFSE DataThe Journal of Immunology, 2007
- Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccinationJournal of Immunological Methods, 2007
- Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trialsJournal of Immunological Methods, 2007